Genomic Vision: Financial Information for the First Quarter of 2023

Revenue from activity +12% in Q1 2023 to €435 thousands Sales of products and services +13% in Q1 2023 to €321 thousands The Company is well funded for 2023 Regulatory News: Genomic

Related Keywords

Bagneux ,France General ,France ,Paris ,United States ,Aaron Bensimon ,Consilium Strategic Communications ,Euronext ,International Investor Relations ,Strategic Communications ,Research Tax Credit ,Research Tax ,Genomic Vision ,Universal Registration Documentation ,Des Meuniers ,Gene Editing ,Support Teams ,Friday September ,Tuesday November ,Investor Relations ,Genomic ,Vision ,Financial ,Information ,First ,Quarter ,023 ,